BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:vixarelimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of vixarelimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06979336-44@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:vixarelimab: Phase 2 readout est. (NCT06979336)
DESCRIPTION:vixarelimab\, phase 2\, Ulcerative Colitis.\nStudy: A Study to 
 Evaluate the Efficacy\, Safety\, and Pharmacokinetics (PK) of RO7837195 in
  Participants With Moderately to Severely Active Ulcerative Colitis (UC)\n
 Estimated primary completion: 25 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vixarelimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06979336
URL:https://assetmemo.bio/drug/vixarelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
